Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 5, 2000, Pages 556-567

  Glue, Paul ^a   Fang, Jane W S ^a   Rouzier Panis, Regine ^b   Raffanel, Claude ^c   Sabo, Ron ^a   Gupta, Samir K ^a   Salfi, Margaret ^a   Jacobs, Sheila ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Centre CAP   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; NEOPTERIN; SYNTHETASE; VIRUS RNA; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ABSORPTION; AREA UNDER THE CURVE; BLOOD; CHEMISTRY; ISOLATION AND PURIFICATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ABSORPTION; ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0034324083     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110973     Document Type: Article

References (30)

1. Reducing the immunogenicity and improving the in vivo activity of tricosanthin by site-directed pegylation
2. Toxicokinetics of PEG12000-interferon (IFN) alfa-2b given by subcutaneous (SC) injection to cynomolgus monkeys for one month
3. Interferon alfa-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomized trial of interferon α-2b plus ribavirin for 48 weeks or 24 weeks versus interferon α-2b plus placebo for 48 weeks the treatment of chronic infection with hepatitis C virus
6. Polyethylene glycol-conjugated pharmaceutical proteins
7. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice
8. Metabolism of protein anticancer agents
9. A pharmacokinetic model for alpha interferon administered subcutaneously
10. Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon
11. A branched methoxy 40Kda polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG-interferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C
12. Phase I study of polyethylene glycol (PEG) interferon alpha-2b (Intron A) in CML patients
13. PEG-interferon-α2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
14. Ribavirin and interferon alpha-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
15. Pharmacokinetics of natural interferon-α in hemodialysis patients
16. Pharmacokinetics of interferon-α in patients with chronic hepatitis C after repetitive intramuscular administration of natural human interferon
17. Pharmacokinetics and pharmacodynamics of interferon β-1a in healthy volunteers
18. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo downregulation of alpha interferon receptors on tumor cells
19. Regulation of interferon receptor expression in human blood lymphoctes in vitro and during interferon therapy
20. Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon
21. Actions of cytokines on the immune response and viral interactions: An overview
22. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
23. Mechanisms of interferon action
24. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
25. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers
26. Clinical and biological effects of recombinant interferon-b administered intravenously daily in phase I trial
27. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-b
28. Pathogenesis, natural history, treatment and prevention of hepatitis C
29. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration